Celltrion Healthcare Co., Ltd.
091990
Rank in Stocks
#2142
Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on... Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on the development, manufacturing, and distribution of biosimilar and biological therapeutic agents for patients around the globe. Its product lineup includes Remsima, a monoclonal antibody biosimilar used to treat various inflammatory and autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease in both adults and children, psoriasis, and psoriatic arthritis. Another significant offering, Truxima, targets conditions like lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, microscopic polyangiitis, and rheumatoid arthritis. Herzuma is prescribed for metastatic breast cancer, early-stage breast cancer, and metastatic gastric cancer. Additionally, Remsima SC provides a treatment option for rheumatoid arthritis. Founded in 1999, the enterprise was initially known as Nexol, Inc. before rebranding to Celltrion Healthcare Co., Ltd. in March 2009. The firm's corporate headquarters are situated in Incheon, South Korea.
Share Price
$57.75
Last synced: 2024-01-11
Market Cap
$9.42B
Change (1 day)
-0.25%
Change (1 year)
0.00%
Country
KR
Trade Celltrion Healthcare Co., Ltd. (091990)
Category
Healthcare
Revenue for Celltrion Healthcare Co., Ltd. (091990)
Revenue in Oct 2026 TTM: 0
According to Celltrion Healthcare Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Celltrion Healthcare Co., Ltd. from 2014 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2022 | $1.56B | 2.97% |
| 2021 | $1.52B | 1.24% |
| 2020 | $1.50B | 57.26% |
| 2019 | $953.35M | 48.78% |
| 2018 | $640.76M | -25.89% |
| 2017 | $864.65M | 37.82% |
| 2016 | $627.36M | 96.07% |
| 2015 | $319.97M | 110.23% |
| 2014 | $152.20M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
